ライフサイエンスコーパス: mg

1 ranasally administered nicotine (0, 0.5, 1.0 mg) across three separate fixed dose experimental sessio

2 1) ) compared to the intact PSF (4.0 +/- 2.0 mg CH(4) m(-2) hr(-1) ) due to prolonged higher WT and m

3 rate among individuals with a bilirubin <2.0 mg/dL (C-statistic, 0.90; 95% CI, 0.82-0.96) and when th

4 12 mg/day; n = 60) or noradrenaline (0.5-3.0 mg/h; n = 60).

5 4.0 mg CH5126766 twice per week (on Monday and Thursday or T

6 tion of the selective agonist imiquimod (5.0 mg/kg) induces a phenotype in offspring characterized by

7 ty lipoprotein [LDL] cholesterol level, 75.0 mg/dL; median triglycerides level, 240 mg/dL; median HDL

8 5.2 mg.kg(-1)) than in leaves (1477.7-8709.0 mg.kg(-1)).

9 HRs for type-specific CVDs and <5.0-mg daily dose use were: 1.69 (95% CI 1.54-1.85) for atri

10 solution available ad libitum (39.25-266.00 mg/kg).

11 /acetate signal), linearity (range 0.05-5.00 mg per assay), sensitivity (limit of detection and quant

12 0 mg/m(2)/dose on days 1-5; cytarabine 2,000 mg/m(2)/dose on days 1-5; and granulocyte-colony stimula

13 male survivors treated with 0 < CED < 4,000 mg/m(2) (P = 3.1 x 10(-4)) and 24 male survivors treated

14 d 24 male survivors treated with CED >=4,000 mg/m(2) and radiotherapy <40 Gray (P = 0.012).

15 clophosphamide equivalent dose (CED) >=4,000 mg/m(2).

16 gnificantly higher CH(4) flux (0.88 +/- 0.03 mg m(-2) hr(-1) ) than spring thaw (0.48 +/- 0.04 mg m(-

17 -2) hr(-1) ) than spring thaw (0.48 +/- 0.04 mg m(-2) hr(-1) ).

18 Terpenes (15.57-41.05 mg/kg), accounting for ~97% of total volatiles, were ass

19 d 40-min after double-blind injection of .08 mg/kg morphine or placebo.

20 pha-pinene as the main volatile (14.47-37.09 mg/kg).

21 Two monkeys were impaired after 0.1 mg/kg olanzapine and two were impaired after 0.3 mg/kg d

22 unconjugated bilirubin increased 4.3 +/- 1.1 mg/dL per day.

23 gh-sensitivity C-reactive protein level, 2.1 mg/L), 12 633 (96.6%) completed the trial with ascertain

24 holesterol level in the two groups was 255.1 mg per deciliter, despite the receipt of maximum doses o

25 omly assigned (1:1) to either anastrozole (1 mg per day, oral) or matching placebo daily for 5 years.

26 5 mg every 4 h, or combined haloperidol at 1 mg and chlorpromazine at 12.5 mg every 4 h, until death

27 e more reliably identified with ICG dose >=1 mg, albumin dissolvent, post-injection lung ventilation,

28 CM and LBG hydrolysates (1 mg/mL) have shown cytotoxic effect and reduced cell viab

29 Isoprenaline (Iso, 1 mg/kg, sc., 10 days) was administered 5 weeks after Px w

30 nds in a fast and low sample consumption (<1 mg) manner.

31 Of the patients receiving NGM282 1 mg or 3 mg, 25% and 42%, respectively, improved liver fi

32 doses of either 4 mg (Cohorts 1 and 2), or 1 mg (Cohort 3).

33 6 months of once per day oral talazoparib (1 mg), followed by definitive surgery.

34 infusion of GSP results in a high yield (~1 mg/g) of trans-Res and improved photostability of infuse

35 Oral administration of NPA101.3 (10 mg/kg/day) completely prevented formation of tumors indu

36 f 25 mM LiCl in sucrose solution (6.50-40.10 mg/kg) or had the same solution available ad libitum (39

37 in a peripheral vessel in the right arm (10 mg/kg, providing therapeutic-level antibody concentratio

38 nificant difference between Mirococept at 10 mg and control was detected; hence the study was stopped

39 e interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10).

40 trial with four groups: placebo, 5 mg/d, 10 mg/d, and 20 mg/d of oral tropisetron.

41 mg/kg cyclosporine A and received either 10 mg/kg prednisolone (P), or LP intravenously on day 0, 3,

42 tO-shIR) were treated with empagliflozin (10 mg/kg/d) or vehicle for 4 weeks.

43 3.8 mg/L (1940.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nmol/L]).

44 3.8 mg/L (1940.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nmol/L]).

45 At the dose of 10 mg/kg (600 mg for flat-dosing), flat-dosing resulted in

46 For >=25 BMI only, 10 mg/dL increase in HDL-C change was associated with decre

47 ow-to-moderate arousal threshold received 10 mg zolpidem or placebo according to a double-blind, rand

48 d study, we investigated whether a single 10 mg dose of the GABA(B) agonist baclofen impaired motor s

49 group, and 60 (75%) of 80 patients in the 10 mg three times weekly group; the most common (>=20% pati

50 C57BL/6 mice were administered with UA (10 mg/body weight) for 12-16 weeks.

51 st prominent and of shortest latency with 10 mg/kg/d GenX exposure.

52 The difference between the 20-mg and 10-mg groups was 0.3 stools (upper boundary of the 98.75% C

53 The difference between the 20-mg and 10-mg groups was 1.2 percentage points (upper boundary of t

54 on as compared with placebo (P = 0.03 for 10-mg brensocatib vs. placebo; P = 0.04 for 25-mg brensocat

55 s of special interest was higher with the 10-mg and 25-mg brensocatib doses, respectively, than with

56 CI, -5.5 to 2.5; P = .47) and between the 10-mg/d vericiguat and placebo groups was -0.5 (95% CI, -4.

57 o received bendamustine on days 1 and 2 (100 mg/m(2) intravenously) with 40 mg of weekly dexamethason

58 plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as compared

59 At Week 48, DOR at 100 mg had a favorable safety profile compared with EFV or D

60 mg/dl or non-high-density cholesterol >=100 mg/dl despite statin therapy.

61 06 [98%] in placebo group, 108 [100%] in 100 mg group, 109 [99%] in 200 mg group, and 111 [100%] in 4

62 102 [94%] in placebo group, 102 [94%] in 100 mg group, 98 [89%] in 200 mg group, and 95 [86%] in 400

63 schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a d

64 tly at a dose of 100 mg/m(2) (maximum of 100 mg) twice daily.

65 paediatric patients mostly at a dose of 100 mg/m(2) (maximum of 100 mg) twice daily.

66 tage points (95% CI, -47 to -16) for the 100-mg dose.

67 venously over 2 h and oral capecitabine 1000 mg/m(2) twice daily on days 1-14 repeated every 3 weeks

68 0 mesh Ottawa sand, injection of a PAC (1000 mg/L) + polyDADMAC (5000 mg/L) suspension created a sorp

69 enous iron was administered as a single 1000 mg dose of ferric carboxymaltose in 100 mL normal saline

70 64 mmol/L) in the lower-target group and 106 mg/dL (2.72 mmol/L) in the higher-target group.

71 , P = .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004

72 M was tested with tap water spiked with 0.11 mg L(-1) of nine different HAAs in a similar reduction e

73 apagliflozin was 22% greater (+0.66 +/- 0.11 mg/kg/min, P < 0.05) than in subjects receiving placebo,

74 H values (9.9) and low DOC concentration (11 mg/L(-)) would maximize triclosan phototransformation ra

75 albumin with infusion of terlipressin (2-12 mg/day; n = 60) or noradrenaline (0.5-3.0 mg/h; n = 60).

76 e study consisting of 3 cohorts (40, 80, 120 mg MMV390048).

77 mal and model control group), metformin (120 mg/kg.bw), and PLPE (600 mg/kg.bw) by oral administratio

78 n at the median dose of 600 (range, 29-1200) mg/day (mean, 8.6 +/- 3.6 mg/kg/day) for a median durati

79 and who had an LDL cholesterol level of 130 mg per deciliter (3.4 mmol per liter) or more and a trig

80 ry 2 weeks (regimen one), or oxaliplatin 130 mg/m(2) administered intravenously over 2 h and oral cap

81 y without (control) or with oral MK-2206 135 mg/week.

82 Median C-reactive protein [138 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), l

83 not show any difference (DR: 0.03(-0.15,0.14)mg/dL vs. control: 0.09(-0.03,0.22)mg/dL;p = 0.797).

84 ws of 728 and 617 mg/8 h (+/- pooled SD: 144 mg/8 h).

85 Isoniazid 10-15 mg/kg daily had similar activity against TB strains with

86 ring early pregnancy was determined to be 15 mg . kg-1 . d-1 (95% CI: 10.4, 19.9 mg . kg-1 . d-1); du

87 randomized to receive isoniazid 5, 10 or 15 mg/kg daily for 7 days (inhA group), and controls with d

88 res mean difference in scores between the 15-mg/d vericiguat and placebo groups was -1.5 (95% CI, -5.

89 ] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacemen

90 26 weeks (n = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and

91 atients received ASP4345 (3, 15, 50, and 150 mg; n = 9 each dose) and 12 patients received placebo.

92 ects design under three drug conditions: 150 mg of the dopamine precursor L-dopa, 2 mg of the D2 rece

93 mum dose evaluated, 200 mg twice a day); 150 mg once daily was established as the RP2D.

94 ipants were randomized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 m

95 more proteinuria (>=150 to <500 versus <150 mg/g), higher systolic blood pressure (>=140 versus 120

96 Nilotinib 150 mg versus matching placebo was taken orally once daily f

97 (34%) were randomly assigned to receive 150 mg S44819 twice a day, 195 (33%) to receive 300 mg S4481

98 uent TSS (61-820 mg L(-1)) and COD (384-1505 mg L(-1)), demonstrating a robust system for treating wa

99 up also received intravenous daratumumab (16 mg/kg of bodyweight, once weekly during cycle one, once

100 ents received selatogrel 8 mg (n = 24) or 16 mg (n = 23) followed by ticagrelor (n = 43) or clopidogr

101 ically useful cathode mass loading up to ~16 mg cm(-2) .

102 intravenously over 2 h, l-folinic acid (175 mg flat dose administered intravenously over 2 h) or d,l

103 Donor creatinine was 10.18 mg/dl with protein (30 mg/dl) present in urinalysis.

104 ticipants with the use of 6 compared with 18 mg/mL nicotine e-liquid.

105 od and Agriculture Organization (FAO) of 0.2 mg/kg, whereas, all cadmium concentrations were below th

106 naloxone-methiodide at a very low dose (0.2 mg/kg; at which naloxone was undetectable in brain tissu

107 PLE-EtOH extract contained 12.2 mg/g of cyanidin-3-glucoside, while other anthocyanins w

108 e higher in fire-affected areas (7.8 +/- 2.2 mg CH(4) m(-2) hr(-1) ) compared to the intact PSF (4.0

109 n berries was considerably lower (76.1-205.2 mg.kg(-1)) than in leaves (1477.7-8709.0 mg.kg(-1)).

110 g . kg-1 . d-1) and IAAO (95% CI: 10.5, 32.2 mg . kg-1 . d-1).

111 mg/kg loading dose in the first week, and 2 mg/kg thereafter) for 9 weeks, starting concomitantly wi

112 intravenous haloperidol dose escalation at 2 mg every 4 h, neuroleptic rotation with chlorpromazine a

113 : 150 mg of the dopamine precursor L-dopa, 2 mg of the D2 receptor antagonist haloperidol, and placeb

114 demonstrated that adjunctive BUP/SAM 2 mg/2 mg was superior to placebo (average difference change fr

115 treal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth

116 t and demonstrated that adjunctive BUP/SAM 2 mg/2 mg was superior to placebo (average difference chan

117 our groups: placebo, 5 mg/d, 10 mg/d, and 20 mg/d of oral tropisetron.

118 A demethylation, and safety vs decitabine 20 mg/m2 IV in the first 2 cycles, with similar efficacy.

119 Patients took lenvatinib 20 mg once daily orally plus pembrolizumab 200 mg intraveno

120 Random allocation to LD-MTX (<=20 mg/wk) or placebo.

121 ccurred in 71 (91%) of 78 patients in the 20 mg three times weekly group, 69 (83%) of 83 patients in

122 kly group, 69 (83%) of 83 patients in the 20 mg twice weekly group, and 60 (75%) of 80 patients in th

123 ns limit liquid nicotine concentration to 20 mg/mL, approximately one-third the level of JUUL product

124 The difference between the 20-mg and 10-mg groups was 0.3 stools (upper boundary of th

125 The difference between the 20-mg and 10-mg groups was 1.2 percentage points (upper bou

126 the 98.75% CI, 1.0), and that between the 20-mg and 5-mg groups was 0.1 stools (upper boundary of the

127 interval [CI], 3.3), and that between the 20-mg and 5-mg groups was 0.7 percentage points (upper boun

128 fidence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for t

129 tarted within 4 days, reaching up to 100-200 mg.L(-1) of dissolved sulfide produced after 19-24 days,

130 mg given with coformulated emtricitabine 200 mg and tenofovir alafenamide 25 mg.

131 isoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg.

132 ovir alafenamide 25 mg and emtricitabine 200 mg, and once-daily oral dolutegravir 50 mg; once-daily o

133 proxil fumarate 300 mg and emtricitabine 200 mg, and once-daily oral dolutegravir 50 mg; or once-dail

134 mulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, or coformulated dol

135 was not reached (maximum dose evaluated, 200 mg twice a day); 150 mg once daily was established as th

136 108 [100%] in 100 mg group, 109 [99%] in 200 mg group, and 111 [100%] in 400 mg group) were included

137 , 102 [94%] in 100 mg group, 98 [89%] in 200 mg group, and 95 [86%] in 400 mg group) were included in

138 e the clinical activity of pembrolizumab 200 mg every 3 weeks, without restriction on prior therapy.

139 mg once daily orally plus pembrolizumab 200 mg intravenously once every 3 weeks, in 3-week cycles.

140 g late pregnancy, it was determined to be 21 mg . kg-1 . d-1 by DAAO (95% CI: 17.4, 24.7 mg . kg-1 .

141 0.15,0.14)mg/dL vs. control: 0.09(-0.03,0.22)mg/dL;p = 0.797).

142 75.0 mg/dL; median triglycerides level, 240 mg/dL; median HDL-C level, 36 mg/dL; and median high-sen

143 owed by a 46 h infusion of fluorouracil 2400 mg/m(2) repeated every 2 weeks (regimen one), or oxalipl

144 ke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cer

145 receive 6 monthly injections of either 1.25 mg bevacizumab (n = 86) or 0.5 mg ranibizumab (n = 84).

146 plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least

147 ed-dose combination tenofovir alafenamide 25 mg and emtricitabine 200 mg, and once-daily oral doluteg

148 itabine 200 mg, and tenofovir alafenamide 25 mg, or coformulated dolutegravir 50 mg, abacavir 600 mg,

149 citabine 200 mg and tenofovir alafenamide 25 mg.

150 uroleptic rotation with chlorpromazine at 25 mg every 4 h, or combined haloperidol at 1 mg and chlorp

151 (n=448) were randomized 1:1:1 to placebo, 25 mg of OM BID, or to pharmacokinetically guided dose titr

152 Patients were randomized 1:1 to receive 25 mg clazakizumab or placebo (4-weekly subcutaneous inject

153 al interest was higher with the 10-mg and 25-mg brensocatib doses, respectively, than with placebo.

154 -mg brensocatib vs. placebo; P = 0.04 for 25-mg brensocatib vs. placebo).

155 additional antimicrobial agent (ie, CRO 250 mg, intramuscular single dose).

156 = 0.733, Cu = 0.234, Zn = 2.91 and I = 0.255 mg L(-1)) infants.

157 g olanzapine and two were impaired after 0.3 mg/kg deschloroclozapine.

158 tors, the CB(2) agonist JWH133 (0.3, 1 and 3 mg/kg, IP) also produced anxiolytic-like effects in TMT-

159 nced NSCLC received nivolumab monotherapy (3 mg/kg every 2 weeks).

160 Of the patients receiving NGM282 1 mg or 3 mg, 25% and 42%, respectively, improved liver fibrosis b

161 subject received 5 days of AVL-3288 (10, 30 mg) and placebo across three separate treatment weeks.

162 le 1: CPX-351; cycle 2: FLAG [fludarabine 30 mg/m(2)/dose on days 1-5; cytarabine 2,000 mg/m(2)/dose

163 rated noninferiority of once-daily 60 mg (30 mg dose-reduced) edoxaban compared with warfarin for pre

164 g development [subcutaneous injections of 30 mg/kg ketamine (KET) on postnatal days 7, 9, and 11] res

165 creatinine was 10.18 mg/dl with protein (30 mg/dl) present in urinalysis.

166 Both groups received 30 mg/m(2) intravenous fludarabine daily for 5 days (days -

167 of bupropion at 26 weeks (n = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28

168 ed diets supplemented with 100, 200, and 300 mg/kg of GML, respectively.

169 e), or leafy green vegetables containing 300 mg nitrate + placebo pills.

170 ombination tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and once-daily oral doluteg

171 ination of tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg.

172 r 50 mg, abacavir 600 mg, and lamivudine 300 mg once daily.

173 daily for 26 weeks followed by nilotinib 300 mg versus placebo for another 26 weeks.

174 Injections of 300 mg/kg of GBP significantly increased the time spent in t

175 low-nitrate vegetables + nitrate pills (300 mg nitrate), or leafy green vegetables containing 300 mg

176 S44819 twice a day, 195 (33%) to receive 300 mg S44819 twice a day, and 193 (33%) to receive placebo

177 curred after 11 days of treatment in the 300 mg cohort.

178 ous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n = 30], or matched placebo

179 doses of apomorphine sublingual film (10-35 mg) were administered until a tolerable full on response

180 Oral cedazuridine/decitabine (100/35 mg) produced similar systemic decitabine exposure, DNA d

181 avenously over 2 h) or d,l-folinic acid (350 mg flat dose administered intravenously over 2 h), and f

182 n living in a hard water (range: 76 to > 350 mg/L CaCO(3) ) area and AE in children.

183 97, RMSECV-0.38 mg/g; R(2)P-0.97, RMSEP-0.36 mg/g).

184 des level, 240 mg/dL; median HDL-C level, 36 mg/dL; and median high-sensitivity C-reactive protein le

185 ents (max.: Arabica: 769 mg/kg, Robusta: 364 mg/kg) followed by a distinct decline.

186 d best performance (R(2)CV-0.97, RMSECV-0.38 mg/g; R(2)P-0.97, RMSEP-0.36 mg/g).

187 infected mice for FG2 HSA nanoparticles (0.4 mg/kg), FG 2 DMSO/saline (0.4 and 8 mg/kg) and a referen

188 ey rats were exposed to nicotine (0.2 or 0.4 mg/kg, subcutaneous) once daily for 7 days.

189 m concentrations were below the limit of 0.4 mg/kg.

190 or trabeculectomy with mitomycin C (MMC; 0.4 mg/ml for 2 minutes).

191 alculations show air-cleaning prevented ~3.4 mg/h of indoor SOA formation due to indoor ozone-monoter

192 oncentrations (maximum 448 ng/g in soil, 3.4 mg/L in groundwater).

193 sulfate the most abundant at 547.8 and 496.4 mg/L, respectively.

194 inistration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes w

195 gain on Day 10 after daily doses of either 4 mg (Cohorts 1 and 2), or 1 mg (Cohort 3).

196 mg/kg thereafter) for 18 doses or weekly (4 mg/kg loading dose in the first week, and 2 mg/kg therea

197 el occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not

198 wenty subjects were randomized to NSI-189 40 mg daily, 80 mg daily, or placebo for 12 weeks.

199 -, co- and post-incubating linezolid (0.4-40 mg/L) with healthy neutrophils relative to those with C5

200 (33.1%) had diuretic doses between 1 and 40 mg/day, and 1085 (16.4%) had diuretic doses >40 mg/day.

201 s in included studies were high (mostly > 40 mg methylprednisolone [or equivalent] per day).

202 day, and 1085 (16.4%) had diuretic doses >40 mg/day.

203 1 and 2 (100 mg/m(2) intravenously) with 40 mg of weekly dexamethasone in 28-day cycles until diseas

204 entage points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for th

205 nously over 2 h), and fluorouracil bolus 400 mg/m(2) administered intravenously over 5 min, followed

206 15 of cycle 1) with either capivasertib 400 mg or matching placebo, orally twice daily on an intermi

207 [99%] in 200 mg group, and 111 [100%] in 400 mg group) were included in the modified intention-to-tre

208 8 [89%] in 200 mg group, and 95 [86%] in 400 mg group) were included in the modified intention-to-tre

209 ter) or more and a triglyceride level of 400 mg per deciliter (4.5 mmol per liter) or less were rando

210 omparing monthly subcutaneous evolocumab 420 mg with placebo in PLHIV with hypercholesterolemia/mixed

211 y subcutaneous injections of evolocumab (420 mg) or placebo.

212 not on apheresis could be up-titrated to 420 mg every 2 weeks.

213 sidual Fe concentration in the acid was 0.43 mg/L.

214 d total analyzed phenolics ranging from 4387 mg/L (Eutric Cambisol) up to 8461 mg/L (Terra Rossa).

215 y against Salmonella typhimurium (MBC = 0.44 mg/mL).

216 mcitabine-nab-paclitaxel along-with ATRA (45 mg/m(2) orally, days 1-15/cycle).

217 = 0.997, Cu = 0.506, Zn = 4.15 and I = 0.458 mg L(-1)) and mothers of full-term (Fe = 0.733, Cu = 0.2

218 ODs and LOQs) within the ranges of 0.01-1.46 mg/L and 0.03-4.9 mg/L, respectively.

219 f either 1.25 mg bevacizumab (n = 86) or 0.5 mg ranibizumab (n = 84).

220 who received a single ketamine infusion (0.5 mg/kg) over 40 min.

221 loperidol at 1 mg and chlorpromazine at 12.5 mg every 4 h, until death or discharge.

222 k, the ammonia concentration dropped to 16.5 mg/L.

223 Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA)

224 For apixaban 2.5 mg twice daily, the median exposure was 2780 ng/(mL.h) f

225 The sensitivities of CRP (cut-off 6.5 mg/L) and PCT (cut-off 0.025 ng/mL) were 52.3% (36.7-67.

226 against TB strains with inhA mutations as 5 mg/kg against drug-sensitive strains.

227 on of both drugs for BAT was determined as 5 mg/mL.

228 to receive ruxolitinib orally, starting at 5 mg twice daily plus corticosteroids, until treatment fai

229 drug-sensitive TB received standard dose (5 mg/kg/day).

230 l comparing amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol

231 or 3 or 8 weeks, then challenged with LPS (5 mg/kg; IP).

232 orticoid dose intake even at lower doses (<5 mg) in 6 immune-mediated diseases.

233 clinical trial with four groups: placebo, 5 mg/d, 10 mg/d, and 20 mg/d of oral tropisetron.

234 emaining only for ACR (>=103 compared with 5 mg/g) and overall nonprostate cancer.

235 Recipients were injected daily with 5 mg/kg cyclosporine A and received either 10 mg/kg predni

236 % CI, 1.0), and that between the 20-mg and 5-mg groups was 0.1 stools (upper boundary of the 98.75% C

237 [CI], 3.3), and that between the 20-mg and 5-mg groups was 0.7 percentage points (upper boundary of t

238 ction to receive coformulated bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 m

239 nd tenofovir alafenamide, or dolutegravir 50 mg given with coformulated emtricitabine 200 mg and teno

240 amide 25 mg, or coformulated dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg once daily.

241 200 mg, and once-daily oral dolutegravir 50 mg; once-daily oral fixed-dose combination tenofovir dis

242 200 mg, and once-daily oral dolutegravir 50 mg; or once-daily oral fixed-dose combination of tenofov

243 aring amiloride/hydrochlorothiazide (5 mg/50 mg daily) with dietary sodium restriction (60 mmol per d

244 M signal in xenograft tumors smaller than 50 mg but not in larger tumors.

245 nd was started on oral eplerenone therapy 50 mg/day for 4 consecutive weeks.

246 :1) to receive intramuscular fulvestrant 500 mg (day 1) every 28 days (plus a loading dose on day 15

247 tion of a PAC (1000 mg/L) + polyDADMAC (5000 mg/L) suspension created a sorptive region that increase

248 urine albumin-to-creatinine ratio 30 to 5000 mg/g and an estimated glomerular filtration rate >=25 to

249 everity of level 2 (blood glucose level, <54 mg per deciliter) or level 3 (severe cognitive impairmen

250 re than 0.5 and they took risperidone at 3-6 mg/day for at least a month before participating in the

251 TWPC containing 3.6 mg of curcumin showed good acceptability.

252 0 (range, 29-1200) mg/day (mean, 8.6 +/- 3.6 mg/kg/day) for a median duration of 3 (range, 0.25-18) m

253 (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafter) for 18 doses or weekly (4 mg/kg loadin

254 l Hg concentrations ranged from 0.49 to 1.60 mg/kg w.w. and showed a significant positive relationshi

255 demonstrated noninferiority of once-daily 60 mg (30 mg dose-reduced) edoxaban compared with warfarin

256 reening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).

257 der, drug injection, and methadone doses <60 mg were independently associated with shorter time to HC

258 Patients received 60 mg selinexor orally on days 1 and 3 weekly until disease

259 centage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16)

260 oformulated dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg once daily.

261 ized to commence subcutaneous dupilumab (600 mg loading dose, then 300 mg once weekly for 15 weeks [n

262 mg, emtricitabine 200 mg, and efavirenz 600 mg.

263 At the dose of 10 mg/kg (600 mg for flat-dosing), flat-dosing resulted in higher medi

264 to add either fostemsavir (at a dose of 600 mg twice daily) or placebo to their failing regimen for

265 iven three times at 12 week intervals or 600 mg given five times, administered at one 4 week interval

266 up), metformin (120 mg/kg.bw), and PLPE (600 mg/kg.bw) by oral administration.

267 with mean respective N flows of 728 and 617 mg/8 h (+/- pooled SD: 144 mg/8 h).

268 icient); ovariectomy+strontium ranelate (625 mg/kg/d) (strontium/estrogen-deficient).

269 cient), sham-surgery+strontium ranelate (625 mg/kg/d) (strontium/estrogen-sufficient); ovariectomy+st

270 s, the achieved LDL-C concentrations were 64 mg/dL (1.64 mmol/L) in the lower-target group and 106 mg

271 d in significantly lower quantities (0.5-0.7 mg/g).

272 mg . kg-1 . d-1 by DAAO (95% CI: 17.4, 24.7 mg . kg-1 . d-1) and IAAO (95% CI: 10.5, 32.2 mg . kg-1

273 ained higher levels of alpha-tocopherol (6.7 mg/100 g), lipids (23.11 g/100 g, manly oleic and linole

274 nge cryogels were found to be 188.3 and 79.7 mg/g cryogel at 25 degrees C, respectively.

275 lipoprotein cholesterol (LDL-C) levels >=70 mg/dl or non-high-density cholesterol >=100 mg/dl despit

276 MACCE reduction only if 1-year LDL-C was <70 mg/dl (hazard ratio: 0.61; 95% confidence interval: 0.40

277 active protein [138 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate [1.1 mmol/L (IQR:

278 e production of maltooligosaccharides (18-75 mg/mL of dextrin syrup).

279 rong rising HMF contents (max.: Arabica: 769 mg/kg, Robusta: 364 mg/kg) followed by a distinct declin

280 ur), and a C-reactive protein level of 203.8 mg/L (1940.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nm

281 ur), and a C-reactive protein level of 203.8 mg/L (1940.9 nmol/L) (normal range, <=10 mg/L [<=95.2 nm

282 les (0.4 mg/kg), FG 2 DMSO/saline (0.4 and 8 mg/kg) and a reference compound, BTZ043, DMSO/saline (0.

283 nce compound, BTZ043, DMSO/saline (0.4 and 8 mg/kg).

284 Forty-seven patients received selatogrel 8 mg (n = 24) or 16 mg (n = 23) followed by ticagrelor (n

285 asma obtained pre- and post-TCZ treatment (8 mg/kg, 6x, monthly) from 12 cAMR patients who failed sta

286 administered intravenously every 3 weeks (8 mg/kg loading dose at first cycle, and 6 mg/kg thereafte

287 us infusion of the same n-apo AI (CSL111, 80 mg/kg) similarly reduced the level of circulating leukoc

288 s were randomized to NSI-189 40 mg daily, 80 mg daily, or placebo for 12 weeks.

289 to long-acting injectable cabotegravir (800 mg given three times at 12 week intervals or 600 mg give

290 ide range of values for influent TSS (61-820 mg L(-1)) and COD (384-1505 mg L(-1)), demonstrating a r

291 from 4387 mg/L (Eutric Cambisol) up to 8461 mg/L (Terra Rossa).

292 Chemotherapy consisted of oxaliplatin 85 mg/m(2) administered intravenously over 2 h, l-folinic a

293 to be 15 mg . kg-1 . d-1 (95% CI: 10.4, 19.9 mg . kg-1 . d-1); during late pregnancy, it was determin

294 in the ranges of 0.01-1.46 mg/L and 0.03-4.9 mg/L, respectively.

295 : 467.8; FRAP: 762.6 ug TE.g(-1), ORAC: 40.9 mg TE.g(-1)).

296 participants were randomized to receive 960 mg of oral co-trimoxazole twice daily (n = 170) or match

297 A high mass activity (1.946 A mg(-1) at 0.45 V) of Pd(delta+)-OCNT is achieved.

298 g reservoir potential of well over a year at mg/day dosing and may not require cold chain storage for

299 with viral loads as low as 52 genome copies/mg.

300 rticles (MNP) with a capacity of 373 pmolPNA/mg and coated with poly(N-acryloylglycine) (PNAG) showed

301 achieved after 4 h, at E/S ratios of 1/150 U/mg, regardless the initial protein concentration.

302 CFU/g and contents of QUE and RES of >200 ug/mg in formulations after freeze-drying.